Our news

GIP ARRONAX and Atonco (Saint Herblain, France) have joined forces to take the next step in the implementation of alpha-immunotherapy for cancer. Their partnership aims to develop and validate the (…)

Arronax's in-house hospital radiopharmacy is providing all the radiopharmaceutical doses planned for the dose escalation phase of an innovative clinical trial aimed at treating castration-resistant prostate cancer. The aim of (…)

Developing Arronax's links with the business world is the mission entrusted to Tony Prézeau as the new director of technology transfer. One week after his arrival at Arronax, Tony Prézeau (…)

This 3rd production line for injectable medicines, which has been operational for a few weeks now, will enable Arronax's In-House Hospital Radiopharmacy to take part in new clinical trials with (…)

3 questions to Jean-François Gestin (CRCI2NA laboratory in Nantes, France), chair of the NOAR (Network Optimized Astatine labeled Radiopharmaceuticals) COST Action funded by the European Union. The members of COST (…)

Program Registration Alexandre Lugat, physician in the nuclear medicine department of the Nantes University Hospital, will lecture on "Targeted alpha therapy of endocrine neoplasias: relevance and state of clinical advancements". (…)

On November 8, 2022, a patient in a clinical trial led by the ICO received a dose of Cu-ATSM produced that day at Arronax. He/she is the 101st patient to (…)

Launched in November 2018 in Nantes, France, the phase 1-2 study evaluating the safety, tolerability and efficacy of 177lu-OPS201 in patients with somatostatin receptor-positive neuroendocrine tumors is nearing completion. The (…)

Resulting from a common will of the CRCINA, Arronax and the University hospital of Nantes, the project submitted by Jean-François Gestin to set up an international clinical network in Europe (…)

The 4th edition of the Nuclear Technologies for Health Symposium (NTHS) was held in Nantes on 13 and 14 February, organised by LabEx IRON in partnership with SIRIC ILIAD and (…)